RecruitingNCT04725422

CHronic Nonbacterial Osteomyelitis International Registry

CHronic Nonbacterial Osteomyelitis International Registry (CHOIR)


Sponsor

Seattle Children's Hospital

Enrollment

2,000 participants

Start Date

Aug 1, 2018

Study Type

OBSERVATIONAL

Conditions

Summary

The objective of the study is to establish a prospective disease registry for chronic recurrent multifocal osteomyelitis (CRMO)/chronic nonbacterial osteomyelitis (CNO) in order to investigate the natural history of the disease and the responses of patients to different clinical managements over 10 years.


Eligibility

Max Age: 21 Years

Plain Language Summary

Simplified for easier understanding

The CHronic Nonbacterial Osteomyelitis (CNO) International Registry collects data on children and young people with CNO — a rare inflammatory bone disease where the immune system attacks bone tissue without any bacterial infection. Because CNO is uncommon, having an international registry allows researchers to study enough cases to understand how it behaves and how it should be treated. Participants will have their medical records, imaging scans, and treatment outcomes entered into the registry. This is an observational study — no experimental treatment is given. The data will help identify what works best for managing CNO. You may be eligible if: - You are 21 years old or younger at the time of enrollment - You have bone edema seen on MRI within 12 weeks of enrollment - You have had a full-body imaging evaluation (whole-body MRI or bone scan) - A bone biopsy has been done to rule out infection or cancer (unless typical disease distribution or associated conditions like IBD, psoriasis, or palmar plantar pustulosis are present) You may NOT be eligible if: - You have a current or past history of malignancy (cancer) - You have active infectious osteomyelitis - There is a contraindication to the treatment being used Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMethotrexate

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUGSulfasalazine

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUGLeflunomide

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUGPamidronate

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUGZoledronic acid

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUGEtanercept

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUGAdalimumab

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUGCertolizumab

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUGInfliximab

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUGGolimumab

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUGNSAID

first-line treatment


Locations(1)

Seattle Children's Hospital

Seattle, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04725422


Related Trials